Household net worth linked to hormonal therapy adherence among patients with breast cancer
the ONA take:
According to a recent study published in the Journal of Clinical Oncology, researchers from the Herbert Irving Comprehensive Cancer Center at New York-Presbyterian/Columbia University Medical Center in New York City have found that household net worth is a major factor in adherence to hormonal therapy among patients with breast cancer that is often overlooked, possibly explaining racial disparities in quality of care.
In order to study the effect of household net worth on quality of care in patients with breast cancer, the researchers analyzed financial and prescription data on 2,437 women aged 50 years and older with early-stage breast cancer who had been prescribed aromatase inhibitors, such as anastrozole or letrozole, between 2007 and 2011. Results showed that income and net worth were directly associated with medication adherence.
The authors note that the findings suggest that healthcare professionals, health insurers, and policy makers need to consider this economic variable so that patients with breast cancer can receive potentially life-saving treatment.
Healthcare providers must engage their patients in a conversation about whether they will be able to afford their medications, so that a solution can be determined to reduce non-adherence and improve outcomes.
Household net worth is a major factor in adherence to hormonal therapy among patients with breast cancer.
- Health Care Expansion Tied to Increased Rates of Surgical Treatment of Thyroid Cancer
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Hormone Refractory Prostate Cancer Responds to Abiraterone Acetate in Some Cases
- Beans, Whole Grains in Diet Beneficial for Colorectal Cancer Survivors
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Rubraca Granted Accelerated FDA Approval for Advanced BRCA-positive Ovarian Cancer
- New Criteria for Appropriate Use of Bone Scintigraphy to Diagnose and Manage Prostate and Breast Cancer
- Primary Care Physicians Surveyed on Breast Cancer Screening Practices
- Low Acculturated Latina Women Reported Breast Cancer Treatment Experience Differently Than Other Groups
- Cost and Complication Rates Differ Among Early Breast Cancer Treatment Options
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|